biostudies-literatureHe XChinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical SciencesThe National HighLevel Hospital Clinical Research FundingFujian Provincial Natural Science Foundation General ProjectNational Key Research and Development Program of China17562848241290663https://www.ebi.ac.uk/biostudies/studies/S-EPMC11528754biostudies-literatureUnknown17<h4>Background</h4>The efficacy of ustekinumab (UST) and infliximab (IFX) in Crohn's disease (CD) patients with intestinal stenosis remains uncertain.<h4>Objective</h4>This study aims to compare the efficacy of UST and IFX in the treatment of CD patients with intestinal stenosis.<h4>Design</h4>This was a retrospective and multicenter cohort study.<h4>Methods</h4>In this retrospective study, we included CD patients treated with IFX or UST at five centers. We assessed the clinical response rate at weeks 12 and 24, steroid-free clinical remission rate at weeks 24 and 52 for overall patients and those with stenosis, and objective examination (intestinal ultrasound and/or endoscopy) response rate at week 52 for stenosis patients.<h4>Results</h4>A total of 211 CD patients (106 IFX and 105 UST) wTherapeutic advances in gastroenterologyEffectiveness comparison between ustekinumab and infliximab for Crohn's disease complicated with intestinal stenosis: a multicenter real-world study.PMC115287542023J0115932023YFC25073002022-I2M-C&amp;T-B-0112022-PUMCH-C-018Yang HQian JHu YZheng WLi YDing XZhan RHe XZhang XLiu AChen YWang YRuan GSun JfalseEffectiveness comparison between ustekinumab and infliximab for Crohn's disease complicated with intestinal stenosis: a multicenter real-world study.<h4>Background</h4>The efficacy of ustekinumab (UST) and infliximab (IFX) in Crohn's disease (CD) patients with intestinal stenosis remains uncertain.<h4>Objective</h4>This study aims to compare the efficacy of UST and IFX in the treatment of CD patients with intestinal stenosis.<h4>Design</h4>This was a retrospective and multicenter cohort study.<h4>Methods</h4>In this retrospective study, we included CD patients treated with IFX or UST at five centers. We assessed the clinical response rate at weeks 12 and 24, steroid-free clinical remission rate at weeks 24 and 52 for overall patients and those with stenosis, and objective examination (intestinal ultrasound and/or endoscopy) response rate at week 52 for stenosis patients.<h4>Results</h4>A total of 211 CD patients (106 IFX and 105 UST) w2024-01-01T00:00:00Z20242026-07-16T09:31:03.898Z2025-04-06T15:23:31.155ZS-EPMC115287543949326010.1177/17562848241290663